Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation |
|---|
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
Sarilumab is an anti-interleukin-6 human monoclonal antibody, such as tocilizumab, which is administered subcutaneously every two weeks for the treatment of moderate to severe active rheumatoid arthritis in adult patients. Despite the effectiveness reported for tocilizumab in the recently published experiences, the need to rapidly find alternative therapies to manage the complications of Covid-19 infection remains extremely high. The lack of clinical experience on the usage of sarilumab in such patients prevents the possibility of adopting early access programs for using commercially available sarilumab (prefilled syringe) packs in patients with severe Covid-19 pneumonia. The present study is aimed to generate a rapid, still robustly documented, evidence on the potential clinical efficacy and tolerability of a further IL-6R antagonist in Covid-19 pneumonia.
Description: Clinical efficacy of sarilumab in adult patients hospitalized due to severe Covid-19 pneumonia based on the proportion of patients who show an improvement of the respiratory function, described as ≥30% decrease in oxygen requirement compared to baseline (as defined as the ratio of O2 flow through the Venturi mask).
Measure: Proportion of patients who show an improvement of the respiratory function Time: 6 weeksDescription: Evaluation of the time to resolution of fever, defined as body temperature ≤36.6°C axilla, ≤37.8°C rectal or tympanic for at least 48 hours without antipyretics in patients with fever at baseline.
Measure: Evaluation of the time to resolution of fever Time: 6 weeksDescription: Evaluation of the viral load on blood and sputum for COVID-19
Measure: Evaluation of the viral load on blood and sputum for COVID-19 Time: Before administration of sarilumab, 48 hours and 96 hours after administrationDescription: Evaluation of the plasma concentration of GM-CSF
Measure: Evaluation of the plasma concentration of GM-CSF Time: Pre-treatment and 96 and 120 hours post-treatmentDescription: Evaluation of the plasma concentration of Il-6
Measure: Evaluation of the plasma concentration of Il-6 Time: Pre-treatment and 96 and 120 hours post-treatmentDescription: Evaluation of the plasma concentration of TNF-α
Measure: Evaluation of the plasma concentration of TNF-α Time: Pre-treatment and 96 and 120 hours post-treatmentDescription: Evaluation of the rate of progression of WBC fraction of immature granulocytes - IG - (absolute count).
Measure: Evaluation of the rate of progression of White Blood Cell (WBC) fraction Time: 96 and 120 hours post-treatmentAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports